系统的可用药物全基因组门德尔随机化确定了阿尔茨海默病的治疗点
Wei-Ming Su1,2, Xiao-Jing Gu3, Meng Dou4
1Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Journal of neurology, neurosurgery, and psychiatry
|June 22, 2023
概括
这项研究确定了三个可药物治疗的基因 (EPHX2,SERPINB1,SIGLEC11) 作为阿尔茨海默病 (AD) 的潜在治疗标. 这些目标显示出有希望的药物开发没有发现的副作用.
科学领域:
- 遗传学 遗传学是一种遗传学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是痴呆的主要原因,目前没有疾病修饰治疗.
- 门德尔随机化 (MR) 是用于药物重新定位和识别新疗法标的宝贵工具.
- 迫切需要新的治疗策略来对抗AD的进展.
研究的目的:
- 为了确定阿尔茨海默病 (AD) 的新型药物可用基因标.
- 分析这些确定的目标的病理生理机制和潜在副作用.
- 为优先考虑AD药物开发提供遗传证据.
主要方法:
- 使用双样本的门德尔随机化 (MR) 方法,将可药物基因与血液和大脑数据的表达定量特征位置 (eQTLs) 集成在一起.
- 使用独立的eQTL数据集进行了鉴定基因的验证.
- 全现象MR分析评估了针对已识别的基因的潜在副作用.
主要成果:
- 在5883个独特的可药物基因中,确定了33个潜在的AD目标,其中5个得到了验证.
- 三个基因 - - 氧化酸酶2 (EPHX2),SERPINB1和SIGLEC11 - - 在血液和大脑组织中显示出显著的关联.
- EPHX2在AD病变发生中的作用可能涉及海马体积,并且没有检测到针对这些三种基因的不良副作用.
结论:
- 遗传证据支持EPHX2,SERPINB1和SIGLEC11作为AD的有希望的治疗点.
- 这些发现可以指导对阿尔茨海默病药物开发工作的优先考虑.
- 准这些基因为AD的疾病修饰治疗提供了潜在的新途径.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
相关概念视频
01:22Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
01:26Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
01:26Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K